The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

Panelists discuss the benefits of implementing bispecific therapy programs in the community setting as well as factors ...

Panelists discuss how therapy sequencing is approached for patients with chronic lymphocytic leukemia (CLL), with a focus on ...

A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved ...

Access and affordability are among the top priorities in health care for Americans who participated in the survey.

Debra Patt, MD, PhD, MBA, MPH, warns that prior authorization barriers are delaying critical cancer treatments and urges a ...

Clayton Irvine, PharmD, MBA, MS, senior manager of oncology care at Mayo Clinic, emphasizes the need for health care ...

Women living in rural Appalachia who are at high-risk of HIV had effective interventions delivered through Facebook.

Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...

On October 14, 2024, the FDA approved a 320-mg single dose of bimekizumab-bkzx (Bimzelx; UCB) in a 2-mL prefilled syringe and autoinjector; both forms are now commercially available in the US.

Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation.